Natalizumab Therapy for Multiple Sclerosis

被引：30
作者：
Chataway, Jeremy [1 ,2 ]
Miller, David H. [1 ,2 ]
机构：
[1] Natl Hosp Neurol & Neurosurg, Queen Sq Multiple Sclerosis Ctr, London WC1N 3BG, England
[2] UCL, Inst Neurol, London WC1N 3BG, England
来源：
NEUROTHERAPEUTICS | 2013年 / 10卷 / 01期
关键词：
Natalizumab; Relapsing remitting MS; Progressive multifocal leucoencephalopathy; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PLACEBO-CONTROLLED TRIAL; PLUS INTERFERON BETA-1A; IMAGING FINDINGS; DOUBLE-BLIND; PML; ENCEPHALOMYELITIS; ANTIBODIES; PHASE-2; RISK;
D O I：
10.1007/s13311-012-0171-4
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The treatment of relapsing remitting multiple sclerosis has witnessed major progress since the first effective disease modifying treatment, -interferon, became available in 1993. One of the most remarkable new treatments has been natalizumab. This review describes the evolution of this humanized anti-alpha 41 monoclonal antibody, from preclinical experimental research through proof-of-concept (phase 1/2) and pivotal (phase 3) clinical trials to the now extensive experience of its use in clinical practice. The future potential and challenges of natalizumab and oral therapies with a similar mechanism of action are also discussed.
引用
收藏
页码：19 / 28
页数：10
相关论文
共 54 条
  • [1] Value of MRI as a surrogate marker for PML in natalizumab long-term therapy
    Ayzenberg, I.
    Lukas, C.
    Trampe, N.
    Gold, R.
    Hellwig, K.
    [J]. JOURNAL OF NEUROLOGY, 2012, 259 (08) : 1732 - 1733
  • [2] Natalizumab reduces visual loss in patients with relapsing multiple sclerosis
    Balcer, L. J.
    Galetta, S. L.
    Calabresi, P. A.
    Confavreux, C.
    Giovannoni, G.
    Havrdova, E.
    Hutchinson, M.
    Kappos, L.
    Lublin, F. D.
    Miller, D. H.
    O'Connor, P. W.
    Phillips, J. T.
    Polman, C. H.
    Radue, E.-W.
    Rudick, R. A.
    Stuart, W. H.
    Wajgt, A.
    Weinstock-Guttman, B.
    Wynn, D. R.
    Lynn, F.
    Panzara, M. A.
    [J]. NEUROLOGY, 2007, 68 (16) : 1299 - 1304
  • [3] Berger Joseph R, 2011, Cleve Clin J Med, V78 Suppl 2, pS8, DOI 10.3949/ccjm.78.s2.03
  • [4] Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
    Bloomgren, Gary
    Richman, Sandra
    Hotermans, Christophe
    Subramanyam, Meena
    Goelz, Susan
    Natarajan, Amy
    Lee, Sophia
    Plavina, Tatiana
    Scanlon, James V.
    Sandrock, Alfred
    Bozic, Carmen
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (20) : 1870 - 1880
  • [5] Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1
    Bozic, Carmen
    Richman, Sandra
    Plavina, Tatiana
    Natarajan, Amy
    Scanlon, James V.
    Subramanyam, Meena
    Sandrock, Alfred
    Bloomgren, Gary
    [J]. ANNALS OF NEUROLOGY, 2011, 70 (05) : 713 - 721
  • [6] Progressive multifocal leukoencephalopathy in HIV-1 infection
    Cinque, Paola
    Koralnik, Igor J.
    Gerevini, Simonetta
    Miro, Jose M.
    Price, Richard W.
    [J]. LANCET INFECTIOUS DISEASES, 2009, 9 (10) : 625 - 636
  • [7] Clifford DB, 2010, LANCET NEUROL, V9, P438, DOI 10.1016/S1474-4422(10)70028-4
  • [8] Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis
    Dalton, CM
    Miszkiel, KA
    Barker, GJ
    MacManus, DG
    Pepple, TI
    Panzara, M
    Yang, M
    Hulme, A
    O'Connor, P
    Miller, DH
    [J]. JOURNAL OF NEUROLOGY, 2004, 251 (04) : 407 - 413
  • [9] Dong-Si T, 2012, MULT SCLER J, V18, P516
  • [10] VCAM-1 ON ACTIVATED ENDOTHELIUM INTERACTS WITH THE LEUKOCYTE INTEGRIN VLA-4 AT A SITE DISTINCT FROM THE VLA-4 FIBRONECTIN BINDING-SITE
    ELICES, MJ
    OSBORN, L
    TAKADA, Y
    CROUSE, C
    LUHOWSKYJ, S
    HEMLER, ME
    LOBB, RR
    [J]. CELL, 1990, 60 (04) : 577 - 584
123456